<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496897</url>
  </required_header>
  <id_info>
    <org_study_id>FP02.2_CS_01</org_study_id>
    <nct_id>NCT02496897</nct_id>
  </id_info>
  <brief_title>Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B
      vaccine, administered as an add-on therapy to entecavir or tenofovir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B
      vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects
      will be randomized to receive low or high dose vaccine, in the presence or absence of IC31®
      adjuvant, or to receive placebo or IC31® adjuvant alone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">June 29, 2018</completion_date>
  <primary_completion_date type="Actual">October 13, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Adverse Events and Clinical Laboratory Abnormalities</measure>
    <time_frame>Throughout the study to day 85</time_frame>
    <description>Adverse Events and Clinical Laboratory Abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>Throughout the study to day 85</time_frame>
    <description>IFN-gamma ELISpot assay specific for FP-02.2 peptides using cryopreserved PBMCs</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>FP-02.2 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of the FP-02.2 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-02.2 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of the FP-02.2 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-02.2 Low Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of the FP-02.2 vaccine with IC31® Adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-02.2 High Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of the FP-02.2 vaccine with IC31® Adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo component.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC31® Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC31® Adjuvant alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FP-02.2 Vaccine</intervention_name>
    <description>Synthetic Peptide Hepatitis B Vaccine</description>
    <arm_group_label>FP-02.2 Low Dose</arm_group_label>
    <arm_group_label>FP-02.2 High Dose</arm_group_label>
    <arm_group_label>FP-02.2 Low Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_label>FP-02.2 High Dose with IC31® Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IC31® Adjuvant</intervention_name>
    <description>IC31® Adjuvant</description>
    <arm_group_label>FP-02.2 Low Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_label>FP-02.2 High Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_label>IC31® Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects aged 18-65 years.

          2. Diagnosed with chronic hepatitis B defined as HBsAg positive for at least 24 months.

          3. Subject has received entecavir or tenofovir for at least 2 years with a stable dose
             for at least 6 months prior to screening.

          4. HBeAg negative for at least 2 years prior to inclusion in the study.

          5. HBV DNA &lt;50 IU/mL for ≥ 12 months

          6. ALT/AST ≤ 1.5 x ULN via the local laboratory at the Screening Visit

          7. Able to give written informed consent to participate

          8. Females should fulfil one of the following criteria:

               1. At least one year menopausal

               2. Surgically sterile

               3. Same-sex relationship

               4. WOCBP not surgically sterilized or with laboratory confirmed menopausal status
                  are required to use a highly effective contraceptive measure with low used
                  dependency from screening until one menstrual cycle after the last dose of IMP
                  (Day 58) such as:

                    -  Combined (oestrogen- and progestogen-containing) hormonal contraception
                       associated with inhibition of ovulation

                    -  Progestogen-only hormonal contraception implants associated with inhibition
                       of ovulation

                    -  Intrauterine device (IUD)

                    -  Intrauterine hormone-releasing system (IUS)

                    -  Bilateral tubal occlusion

                    -  Vasectomised partner - must have had medical assessment of successful
                       surgery.

        From screening until one menstral cycle after the last dose of IMP (day 57).

        Subjects who practice true abstinence or who exclusively have same sex partners need not
        use contraception, provided it is in line with their preferred and usual lifestyle.
        Periodic abstinence (eg calendar, ovulation, symptothermal, post-ovulation methods) and
        withdrawal are not acceptable methods of contraception. Should any such subject stop
        practicing true abstinence, they must use contraception as described above.

        Males should fulfil one of the following criteria:

          -  Surgically sterile

          -  Willing to abstain from sexual intercourse or use a reliable form of contraception
             (e.g. condom), if having sex with a pregnant or non-pregnant woman of childbearing
             potential, from screening until 3 months after the final dose of IMP.

          -  Surgically sterilised or post-menopausal female partner or same-sex relationship.

        Exclusion Criteria:

          1. Liver disease other than chronic hepatitis B (a diagnosis of steatosis is permitted
             providing inclusion criterion 6 is met).

          2. Evidence of Liver cirrhosis on Fibroscan screening (Liver cirrhosis is defined as a
             Fibroscan measurement of &gt;11.5 KPa), or previous history or evidence of cirrhosis on
             radiological imaging, Fibroscan or liver biopsy.

          3. Positive serology for HIV-1 or HIV-2 or HCV or HDV antibodies.

          4. Immunodeficient or autoimmune conditions due to disease or medication e.g. systemic
             steroids within previous 12 weeks. (Topical or inhaled steroids are permissible).

          5. Clinically relevant co-morbidity, e.g. autoimmune disease.

          6. Clinically relevant anaemia or leukopenia in the opinion of the investigator.

          7. Cancer or treatment for cancer within 3 years prior to screening excluding basal cell
             carcinoma of the skin, which is allowed.

          8. Known or suspected intolerance or hypersensitivity to the IMP or closely related
             compounds or any of the stated ingredients.

          9. Receipt of any IMP within 90 days prior to screening or currently receiving IMP or
             intent to receive IMP.

         10. Current substance or alcohol abuse that in the opinion of the Investigator would
             interfere with compliance or with interpretation of study results.

         11. Any condition that in the opinion of the Investigator might interfere with study
             objectives.

         12. Pregnant or breastfeeding.

         13. Subjects should not have received, during the 6 month period prior to screening, any
             medications or other treatments that may adversely affect the immune system such as
             allergy injections, immunoglobulins, interferons, cytotoxic drugs or other drugs known
             to be frequently associated with significant major organ toxicity, or systemic
             corticosteroids (oral or injectable).

             Immunosuppressive treatment such as azathioprine or mercaptopurine is not permitted 6
             months prior to screening.

         14. Administration of live vaccines (such as live influenza vaccinations or live travel
             vaccinations) from 10 days prior to the screening visit until Day 85.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Thursz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Busan Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and The London School of Medicine and Dentistry, Blizzard Institiue</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital and Medical School</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London - St Mary's Campus</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennine Acute Hospitals</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals, Bradford Royal Infirmary</name>
      <address>
        <city>North Yorkshire</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre, Nottingham Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

